A study has been done to prove that low dosage of aspirin has nothing to do with aged healthy people living a long life. This study involved thousands of very healthy and old aged people who have never had heart related problems or stroke. This research was done because it was not clearly stated the importance and the risk that might be involved in elderly people taking low levels of aspirin. A research that had been done some time back had shown that low dose of aspirin can actually reduce the chances of one getting vascular diseases like heart attack. This research mainly focused on middle-aged people and diseases that may affect the heart.
Aspirin in Reducing Events in the Elderly (ASPREE) began in 2010. Approximately 16,703 people who were 70 years old were recruited in Australia and 2411 in United States. The study will end in early 2019. People with any kind of physical disability or any form of diseases were not involved in the study. 19,114 people were participants of the study. They were divided into two groups. One group that had 9525 people were given 100 milligrams of aspirin and the other 9589 were to take placebo daily.
Generally, the results of the study this far shows that taking low levels of aspirin on a daily basis had completely no effect on disability free survival compared with placebo. The chances of non-fatal cardiovascular and fatal stroke are almost the same for those who took aspirin and placebo. The research that was done recently has confirmed that aspirin can cause bleeding in parts of the body like the stomach. Some of the participants have died of cancer during the period of study. The most disturbing fact is that most of the people who have died during the study are the ones who take the aspirin. The reason why it is disturbing is that aspirin has been known to reduce the risk of cancer by many researches that have been conducted in the past. Nineteen percent of the people who have died during the study have suffered from stroke and five percent have died due to major bleeding.
Evan Hadley, who is the director of the division of Geriatrics and Clinical Gerontology at NIA, promised that the participants of the study would receive follow up. They will also be observed closely for any effects of the results of the study like cancer.